Investors

Company News

MetaStat Elevates Jerome B. Zeldis, M.D., Ph.D. to Chairman of the Board and Appoints Douglas A. Hamilton, MetaStat’s President and CEO to its Board of Directors

Download PDF

Renown Drug Developer Becomes MetaStat’s Chairman of the Board

BOSTON--(BUSINESS WIRE)-- MetaStat, Inc. (OTCQB:MTST), a pre-commercial biotechnology company focused on the development and commercialization of companion diagnostics and anti-metastatic therapeutics in the novel cancer treatments in drugs, today announced the promotion of Jerome B. Zeldis, M.D., Ph.D. from Vice Chairman to Chairman and the appointment of Douglas A. Hamilton, MetaStat’s President and Chief Executive Officer, to its board of directors in connection with a restructuring of MetaStat’s board.

Dr. Zeldis stated, “MetaStat has an exciting technology platform based on the novel mechanisms that drive cancer metastasis and overcome tumor resistance to certain therapeutics, creating the potential to discover novel cancer drugs. I look forward to working with Doug and the MetaStat team in solidifying our mission to discover and develop truly novel approaches for treating a variety of cancers.”

Mr. Hamilton said, “I am delighted Jerry is leading MetaStat’s Board of Directors and honored to serve on the board with him. We have a shared vision for the future of the Company, seeing multiple opportunities to make significant advances in treating cancer.” Mr. Hamilton continued, “Our driver-based diagnostic biomarkers are also therapeutic targets for the development of anti-metastatic drugs and combination therapies to overcome drug resistance. We plan to leverage our driver-based biomarkers and expand strategic partnerships to unlock opportunities in oncology.”

Please see the company’s current report on Form 8-K filed with the Securities and Exchange Commission on May 8, 2017 for full details on the board restructuring, including the resignations of Messrs. Berman, Goodeve and Bronsther.

Dr. Zeldis is the Chief Medical Officer of Sorrento Therapeutics, Inc., and previously served as Chief Medical Officer of Celgene Corporation and Chief Executive Officer of Celgene Global Health until June 2016. Prior to joining Celgene in 1997, Dr. Zeldis held positions at Sandoz Research Institute and Janssen Research Institute in both clinical research and medical affairs. He currently serves as Chairman of the board of Alliqua and Trek Therapeutics, in addition to board positions at PTC Therapeutics and Soligenix. He was Assistant Professor of Medicine at Harvard Medical School, Associate Professor of Medicine at University of California, Davis, Clinical Associate Professor of Medicine at Cornell Medical School, and Professor of Clinical Medicine at the Robert Wood Johnson Medical School. Dr. Zeldis received BA and MS degrees from Brown University, and M Phil, MD, and PhD degrees from Yale University. Dr. Zeldis has published 122 peer-reviewed articles and is a named inventor on 43 U.S. patents.

Mr. Hamilton has been President and CEO of MetaStat since June 2015. Previously, Mr. Hamilton served as CFO for SEA Medical Systems and since 2007, Partner at New Biology Ventures, a life-sciences incubator accelerator and consulting firm. From 1999 to 2006, Mr. Hamilton served as CFO and COO for Javelin Pharmaceuticals, purchased by Hospira, where he led the company to commercialization and through its successful national markets up-listing. Prior to Javelin, Mr. Hamilton was the CFO and Director of Business Development for PolaRx Biopharmaceuticals (now Teva Pharmaceuticals). Mr. Hamilton held positions at Amgen and Pfizer in clinical research and product development, sales and marketing at Pharmacia Biotechnology (now GE Healthcare Life Sciences), and research at Connaught Laboratories (now Sanofi-Pasteur). Mr. Hamilton earned his honors Bachelor of Science degree from the Department of Medical Genetics at the University of Toronto and his MBA from the Ivey Business School at Western University.

About MetaStat, Inc.

MetaStat is a pre-commercial biotechnology company focused on the discovery, development and commercialization of diagnostics tests that are prognostic for risk of cancer metastasis, companion diagnostics to predict drug response and therapeutics to prevent aggressive cancer from spreading. MetaStat’s driver-based diagnostic and therapeutic discovery platform technology is based on the pivotal role of the Mena protein and its isoforms, a common pathway for the development of metastatic disease and drug resistance in all epithelial-based solid tumors. MetaStat is based in Boston, MA.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K and its other filings filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

MetaStat
Rick Pierce, VP
617-531-0874
rpierce@metastat.com

Source: MetaStat, Inc.